---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265779672.md"
description: "Novo Nordisk and Eli Lilly rebut reports of a partnership with the electronic health website Mangoceuticals Inc. in the field of weight loss drugs"
datetime: "2025-11-13T19:07:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265779672.md)
  - [en](https://longbridge.com/en/news/265779672.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265779672.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/265779672.md) | [繁體中文](https://longbridge.com/zh-HK/news/265779672.md)


# 

Novo Nordisk and Eli Lilly refute reports of a partnership with the electronic health website Mangoceuticals Inc. in the field of weight loss drugs

### Related Stocks

- [Novo Nordisk A/S (NVO.US)](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

- [Novo Nordisk slashes Wegovy prices to court uninsured patients](https://longbridge.com/en/news/281206892.md)
- [Novo Nordisk A/S Approves Final Dividend for 2025, Payable in March 2026](https://longbridge.com/en/news/280694679.md)
- [Novo Nordisk Launches Discounted Subscription Program for Wegovy Obesity Drugs -- Update](https://longbridge.com/en/news/281201382.md)
- [UK Regulator Recommends Novo Nordisk's Wegovy for People at Risk of Heart Attacks, Strokes](https://longbridge.com/en/news/281294814.md)
- [NHS clears Wegovy to reduce risk of heart attack and stroke](https://longbridge.com/en/news/281323250.md)